Skip to main content

Table 2 Clinical features of LUSC patients in two risk groups

From: A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma

Feature

High-risk group

(n = 251)

Low-risk group

(n = 244)

n

%

n

%

Age

  <=65

86

34.26

103

42.21

  >65

163

64.94

137

56.15

  Unknow

2

0.80

4

1.64

Status

  Alive

128

51.00

157

64.34

  Dead

123

49.00

86

35.25

  Gender

   Female

71

28.29

58

23.77

   Male

180

71.71

186

76.23

Stage

  Stage I

127

50.60

114

46.72

  Stage II

75

29.88

85

34.84

  Stage III

42

16.73

41

16.80

  Stage VI

5

1.99

2

0.82

  Unknow

2

0.80

2

0.82

T stage

  T1

59

23.51

55

22.54

  T2

146

58.17

142

58.20

  T3

36

14.34

34

13.93

  T4

10

3.98

13

5.33

M stage

  M0

207

82.47

200

81.97

  M1

5

1.99

2

0.82

  Unknow

39

15.54

42

17.21

N stage

  N0

171

68.13

145

59.43

  N1

53

21.12

75

30.74

  N2

21

8.37

19

7.79

  N3

3

1.20

2

0.82

  Unknow

3

1.20

3

1.23